SAFC complete Jerusalem expansion

SAFC has completed the expansion of its fermentation capabilities in Jerusalem, Israel. The 5000m² facility, which is expected to begin production during October 2010, will focus on niche fermentation of APIs and bulk drugs, producing secondary metabolites (antibiotic-like molecules), cytotoxins and large-molecule proteins. 3000m² of the new facility has been designed to be Biosafety Level 2 compliant which provides the company the capability for manipulation of human pathogens.
GEN